One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (PANDA)

Ferring

Status and phase: Completed; Phase 3

Conditions: Prostate Cancer

Treatments: Drug: Goserelin; Drug: Degarelix

Study type: Interventional

Funder types: Industry

Identifiers

NCT01744366

000006

Details and patient eligibility

About

One month degarelix/comparator treatment for prostate cancer in Chinese population

Enrollment: 285 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chinese male over 18 years
• Adenocarcinoma of the prostate
• Relevant disease status based on lab values and as judged by the physician
• Life expectancy of at least a year

Exclusion criteria

• Previous hormonal treatment for prostate cancer
• Considered to be candidate for curative therapy
• Risk or history of any serious or significant health condition
• Has received an investigational drug within the last 28 days and no previous treatment with degarelix

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

285 participants in 2 patient groups

Degarelix

Experimental group

Description:

Degarelix 240/80 mg

Treatment:

Drug: Degarelix

Goserelin

Active Comparator group

Description:

Goserelin 3.6 mg

Treatment:

Drug: Goserelin